RMNI vs. OPRX, PAYS, PRTH, ZFOX, DHX, STCN, SCOR, EGIO, MCHX, and EEX
Should you be buying Rimini Street stock or one of its competitors? The main competitors of Rimini Street include OptimizeRx (OPRX), Paysign (PAYS), Priority Technology (PRTH), ZeroFox (ZFOX), DHI Group (DHX), Steel Connect (STCN), comScore (SCOR), Edgio (EGIO), Marchex (MCHX), and Emerald (EEX). These companies are all part of the "business services, not elsewhere classified" industry.
OptimizeRx (NASDAQ:OPRX) and Rimini Street (NASDAQ:RMNI) are both small-cap computer and technology companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, community ranking, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.
76.5% of OptimizeRx shares are owned by institutional investors. Comparatively, 73.8% of Rimini Street shares are owned by institutional investors. 4.4% of OptimizeRx shares are owned by insiders. Comparatively, 41.3% of Rimini Street shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, OptimizeRx had 12 more articles in the media than Rimini Street. MarketBeat recorded 14 mentions for OptimizeRx and 2 mentions for Rimini Street. OptimizeRx's average media sentiment score of 0.89 beat Rimini Street's score of 0.12 indicating that Rimini Street is being referred to more favorably in the news media.
OptimizeRx has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Comparatively, Rimini Street has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500.
Rimini Street has a net margin of 5.02% compared to Rimini Street's net margin of -23.10%. Rimini Street's return on equity of -6.96% beat OptimizeRx's return on equity.
Rimini Street received 9 more outperform votes than OptimizeRx when rated by MarketBeat users. Likewise, 63.49% of users gave Rimini Street an outperform vote while only 63.16% of users gave OptimizeRx an outperform vote.
OptimizeRx currently has a consensus target price of $16.00, suggesting a potential upside of 26.08%. Rimini Street has a consensus target price of $4.50, suggesting a potential upside of 85.95%. Given OptimizeRx's higher possible upside, analysts clearly believe Rimini Street is more favorable than OptimizeRx.
Rimini Street has higher revenue and earnings than OptimizeRx. OptimizeRx is trading at a lower price-to-earnings ratio than Rimini Street, indicating that it is currently the more affordable of the two stocks.
Summary
Rimini Street beats OptimizeRx on 12 of the 18 factors compared between the two stocks.
Get Rimini Street News Delivered to You Automatically
Sign up to receive the latest news and ratings for RMNI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RMNI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rimini Street Competitors List
Related Companies and Tools
